Much of it seems to be regular upkeep of existing facilities. They’re the 3rd largest pharma company in the world, so they have a sizeable presence almost everywhere already. This seems just like PR for things that have likely been planned long before now.
As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight US states. The investment will include:
-Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California
-A state-of-the-art gene therapy manufacturing facility in Pennsylvania
-A new 900,000 square foot manufacturing centre to support Roche’s expanding portfolio of next generation weight loss medicines (location to be announced)
-A new manufacturing facility for continuous glucose monitoring in Indiana
-A new R&D centre in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as hub for our new cardiovascular, renal and metabolism research and development efforts
-Significant expansion and upgrading of our existing pharmaceuticals and diagnostics R&D centres in Arizona, Indiana and California
Roche is a Swiss company with a strong heritage in more than 130 countries globally.
We are proud of our 110 year legacy in the United States.
Much of it seems to be regular upkeep of existing facilities. They’re the 3rd largest pharma company in the world, so they have a sizeable presence almost everywhere already. This seems just like PR for things that have likely been planned long before now.
From Roche’s Press Release: